Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)(COMPLETED)

This study has been completed.

Sponsor:

Information provided by:

Merck

ClinicalTrials.gov Identifier:

NCT00042029

First received: July 22, 2002

Last updated: March 15, 2011

Last verified: March 2011

History of Changes

Purpose

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Condition	Intervention	Phase
Major Depressive Disorder	Drug: MK0869, aprepitant Drug: Comparator: placebo	Phase 3

Study Type:	Interventional
Study Design:	Endpoint Classification: Safety/Efficacy Study Primary Purpose: Treatment
Official Title:	A Double-Blind, Multicenter, Placebo-Controlled Study of MK0869 in the Treatment of Patients With Major Depressive Disorder

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Aprepitant Fosaprepitant Fosaprepitant dimeglumine

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

HAMD-17 total score; Tolerability

Secondary Outcome Measures:

CGI-I Scale score; Sheehan Disability Scale

Estimated Enrollment:	286
Study Start Date:	June 2002
Study Completion Date:	October 2003

Detailed Description:

The duration of treatment is 8 weeks.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Patients with Major Depressive Disorder

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00042029

Show 32 Study Locations

Sponsors and Collaborators

Merck

More Information

Publications:

Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of Efficacy of the Substance P (Neurokinin(1) Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder. Biol Psychiatry. 2005 Oct 21; [Epub ahead of print]

Responsible Party:	Vice President, Late Stage Development Group Leader, Merck Sharp & Dohme Corp
ClinicalTrials.gov Identifier:	NCT00042029 History of Changes
Other Study ID Numbers:	2006_409, Formally-8DL718, MK0869-073
Study First Received:	July 22, 2002
Last Updated:	March 15, 2011
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Aprepitant
Antiemetics

Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Gastrointestinal Agents

ClinicalTrials.gov processed this record on June 17, 2013

To Top